Nasdaq
$1.03▲ 0.98%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $7.5MShares out 7.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
15- 5d agoAfter-hours26.10.20 06:286-KKey event#●●●#●●●
Chemomab Therapeutics Ltd.
Chemomab Therapeutics has entered into Amendment No. 2 to its merger agreement regarding its redomiciliation and merger with Scipher Medicine. The amendment reduces the number of shares outstanding for the combined company from 10 million to 5 million and adjusts the information reporting requirements and payment mechanics for Contingent Value Rights (CVR) holders.…more
$1.03+0.98%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 5d agoAfter-hours26.10.20 06:27S-4/AOffering
Chemomab Therapeutics Ltd.
Chemomab Therapeutics has filed an amended Form S-4 registration statement regarding its merger with Snowdrift Parent Corporation and Scipher Medicine Corporation. As part of the merger, Chemomab shareholders will receive Contingent Value Rights (CVRs) worth up to $50 million, payable upon the initiation of specific clinical trials or the disposition of the product.…more
$1.03+0.98%vs prev closeView filingShare - 9.30After-hours26.10.01 05:056-KKey event
Chemomab Therapeutics Ltd.
Chemomab Therapeutics has entered into an amendment to its merger agreement with Scipher Medicine to facilitate its redomiciliation to the U.S. The amendment introduces a formula-based exchange ratio to ensure the combined company has exactly 10,000,000 shares outstanding immediately following the merger. The transaction is expected to close in the fourth quarter of 2026, with the combined entity planning to list on Nasdaq under the ticker symbol 'SCIP'.…more
$1.03+0.98%vs prev closeView filingShare
14 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.30After-hours26.10.01 05:20#●●●
Chemomab Amends Merger Agreement Ahead Of U.S. Redomiciliation And Scipher Combination…more
Chemomab has amended its merger agreement with Scipher Medicine in preparation for its redomiciliation to the United States. This adjustment is a strategic step to facilitate the corporate restructuring and the upcoming business combination.…more
$1.03+0.98%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 8.19Pre-market26.08.19 21:54
●●●●●●●● ●●●●● ●●●●●●
Chemomab Therapeutics reported a quarterly loss of $0.24 per share, missing the analyst consensus estimate of a $0.15 loss. While the loss narrowed compared to the same period last year, the company failed to meet market expectations.…more
$1.03+0.98%vs prev closeShareBenzinga - 8.19Pre-market26.08.19 21:26
●●●●●●●● ●●●●● ●●●●●●
Chemomab is advancing its merger with Scipher Medicine to focus on developing a rheumatoid arthritis treatment using an AI-driven platform. The company reported continued net losses for the second quarter while planning a concurrent $30 million private placement.…more
$1.03+0.98%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report